Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis in new users of antiepileptics.
about
Toxic epidermal necrolysis and Stevens-Johnson syndromeMulti-indication carbamazepine and the risk of severe cutaneous adverse drug reactions in Korean elderly patients: a Korean health insurance data-based studyHLA-A*24:02 as a common risk factor for antiepileptic drug-induced cutaneous adverse reactionsRechallenge with lamotrigine after a rash: a prospective case series and review of the literature.Lamotrigine-induced rash: Can we stop worrying?New generation antiepileptic drugs: what do they offer in terms of improved tolerability and safety?Severe skin complications in patients treated with antidepressants: a literature review.Severe cutaneous reactions caused by barbiturates in seven Iranian children.The current understanding of Stevens-Johnson syndrome and toxic epidermal necrolysis.Maintenance therapies in bipolar disorders.Recommendations for HLA-B*15:02 and HLA-A*31:01 genetic testing to reduce the risk of carbamazepine-induced hypersensitivity reactions.[Toxic epidermal necrolysis induced by phenobarbital in a Rwandan child: report of a case].Antiepileptic drugs in the treatment of neuropathic pain.Common risk allele in aromatic antiepileptic-drug induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Han Chinese.Stevens-Johnson syndrome due to concomitant use of lamotrigine and valproic acid.Carbamazepine and phenytoin induced Stevens-Johnson syndrome is associated with HLA-B*1502 allele in Thai population.A rare case of toxic epidermal necrolysis with unexpected Fever resulting from dengue virusPharmacotherapeutics of epilepsy: use of lamotrigine and expectations for lamotrigine extended releaseThe International Society for Bipolar Disorders (ISBD) consensus guidelines for the safety monitoring of bipolar disorder treatments.Carbamazepine hypersensitivity: progress toward predicting the unpredictablePhenytoin-induced Lyell's syndrome.Rash in psychiatric and nonpsychiatric adolescent patients receiving lamotrigine in Korea: a retrospective cohort study.Phenytoin Induced Erythema Multiforme after Cranial Radiation Therapy.Toxic epidermal necrolysis - management issues and treatment options.Pharmacogenetic testing prior to carbamazepine treatment of epilepsy: patients' and physicians' preferences for testing and service delivery.Lamotrigine for neuropathic pain.Levetiracetam induced psoriasiform drug eruption: a rare case report.Current understanding of delayed anticonvulsant hypersensitivity reactions.Safety and tolerability of mood-stabilising anticonvulsants in the elderly.Toxic epidermal necrolysis associated with radiotherapy and phenytoin in a patient with non-Hodking's lymphoma: A case reportPractical considerations for carbamazepine use in bipolar disorder.Lamotrigine and its applications in the treatment of epilepsy and other neurological and psychiatric disorders.Currently available antiepileptic drugs.Idiosyncratic adverse reactions to antiepileptic drugs.The treatment of the first seizure: the risks.Stevens-Johnson syndrome: pathogenesis, diagnosis, and management.Two cases of Stevens-Johnson syndrome following intake of klavox with review of literature.The effect of lamotrigine on epilepsy.Stevens Johnson Syndrome associated with Lamotrigine.Genetic predisposition of life-threatening antiepileptic-induced skin reactions.
P2860
Q21202877-ED06626D-2E01-44A9-ADE6-4AE6566639ECQ28538150-59DF97A8-C622-4B01-91F7-9B57E15318AAQ33788588-7DD6636D-68B6-4476-97D1-73C781B7D4FDQ33900131-7997F35F-687B-4EFF-B3F2-3433362E6B54Q33948129-9DC1E167-44E8-424D-914A-54F1454D7C02Q33949491-53130296-19D7-47D8-994D-1817BB54A612Q33955626-97793018-AEDE-4352-94DC-E78155E1D5E0Q34092068-4ED2075B-9946-4270-AFB8-0D8DF35EB8D9Q34225850-5441F1A2-4B4E-4B4F-92FD-AE4FCD83758EQ34268760-77C77AAC-7B4E-4055-A2A8-454EFA935645Q34408357-FC697B7C-6399-4640-BF52-968373B8FA7BQ34496798-8BFDE5E4-CB0C-4E5B-AF7E-BC1A05AA5EA0Q34580010-DAF3B049-24EE-4593-B5F4-37F4440025F2Q34617803-39B26000-D530-4092-9931-135EED135CC4Q34618205-3C7AF698-1A65-4F6D-8D9A-F80E5D325255Q34797826-3E1D7931-EAA6-423F-A877-FDC26B6A7EDEQ34816519-0F44E8D4-C8EC-4656-B073-A267347A9509Q34942400-1343AA5F-669E-4D1A-A86A-AD9E3A938893Q34998063-55A0A3A7-03DD-488E-BEDE-C8F584DD6129Q35562371-07983165-17BD-4B64-917B-84C049E02EC3Q35982729-6A10D743-9548-4879-834D-475031C309F9Q36024152-DA967052-BA3D-40C2-9E71-A4BF837E4653Q36044126-E9D151BD-AD63-4D71-A1A3-CBACF317A71DQ36154190-9D0C84FC-0CEB-424A-A522-CB4470D62AA8Q36243674-19795A1A-6EE7-418E-A7EC-BA980C5DADC5Q36307850-A5B9D499-92D5-47A2-B03B-E5BF9713A920Q36346258-0508F903-C16A-4DAC-9420-6B1B8009441EQ36444480-BA3AAD81-9BD0-4145-A68D-F31416CC3FB5Q36446899-A49A7297-A5BF-44FC-BAF5-4892E6976781Q36472561-580E43D1-B2DD-4800-876E-796E5F0A5F0BQ36506812-3F9A1F38-FF9D-424B-84CA-DD9131363C0DQ36673011-ADDE86FC-F928-4381-9C5C-27BDCCBCE131Q36697463-1324888F-0417-471A-9BF3-1180BBAC6659Q36770454-ACBED5D5-2394-4E82-BCCE-621B10A043A9Q37053861-A0A6B08E-96DF-4389-B914-25F0620186E2Q37091877-48E640AD-2329-4144-AAF7-FA1BE7358A73Q37243882-239B679D-0392-4DF9-8B4E-CC81B2BCD665Q37311668-908975F8-1284-49CB-8C6A-7D2DA6AB1474Q37526985-06CEDC7E-808D-4497-B525-AD61A176CFE3Q37650570-0B4D5460-C677-4072-ACCA-61D765CBD593
P2860
Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis in new users of antiepileptics.
description
2005 nî lūn-bûn
@nan
2005 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Risk of Stevens-Johnson syndro ...... n new users of antiepileptics.
@ast
Risk of Stevens-Johnson syndro ...... n new users of antiepileptics.
@en
type
label
Risk of Stevens-Johnson syndro ...... n new users of antiepileptics.
@ast
Risk of Stevens-Johnson syndro ...... n new users of antiepileptics.
@en
prefLabel
Risk of Stevens-Johnson syndro ...... n new users of antiepileptics.
@ast
Risk of Stevens-Johnson syndro ...... n new users of antiepileptics.
@en
P2093
P1433
P1476
Risk of Stevens-Johnson syndro ...... n new users of antiepileptics.
@en
P2093
John Messenheimer
Juergen Schlingmann
Maja Mockenhaupt
Pat Tennis
P304
P356
10.1212/01.WNL.0000156354.20227.F0
P407
P577
2005-04-01T00:00:00Z